Skip to content
2000
Volume 20, Issue 6
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Prostate cancer (PCa) ranks the second most diagnosed cancers among men globally and the sixth leading cause of cancer-related deaths. Advanced prostate cancer can be defined as the recurrence after definitive therapies (radical prostatectomy or external beam radiotherapy) and de novo metastasis (metastasis without prior treatment). Advanced PCa can be categorized as metastatic hormone sensitive prostate cancer (mHSPC), non-metastatic castration resistant prostate cancer (nmCRPC), and metastatic castration resistant prostate cancer (mCRPC). Management of advanced PCa often involves castration to reduce testosterone levels, which can be achieved by gonadotropin releasing hormone antagonists such as degarelix and relugolix. Degarelix is injectable while relugolix is an orally administered form of GnRH antagonist. This review aims to explore the latest pharmacological aspects of these drugs to inform treatment decisions for advanced PCa.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855324045240902100500
2024-09-19
2025-10-23

  • From This Site

    /content/journals/cdth/10.2174/0115748855324045240902100500
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. Prostate Cancer – Advanced: Symptoms, diagnosis & treatment - Urology Care Foundation.Available from: https://www.urologyhealth.org/urology-a-z/a_/advanced-prostate-cancer
  3. Treatment by cancer type. NCCN.Available from: https://www.nccn.org/guidelines/category_1
  4. SwamiU. McFarlandT.R. NussenzveigR. AgarwalN. Advanced prostate cancer: Treatment advances and future directions.Trends Cancer20206870271510.1016/j.trecan.2020.04.01032534790
     [Google Scholar]
  5. KimuraT. SasakiH. AkazawaK. EgawaS. Gonadotropin-releasing hormone antagonist: A real advantage?Urol Oncol2015337322328
     [Google Scholar]
  6. ParkerC. CastroE. FizaziK. HeidenreichA. OstP. ProcopioG. TombalB. GillessenS. ESMO Guidelines Committee. Electronic address: [email protected] Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann. Oncol.20203191119113410.1016/j.annonc.2020.06.01132593798
     [Google Scholar]
  7. MottetN. BellmuntJ. BollaM. BriersE. CumberbatchM.G. De SantisM. FossatiN. GrossT. HenryA.M. JoniauS. LamT.B. MasonM.D. MatveevV.B. MoldovanP.C. van den BerghR.C.N. Van den BroeckT. van der PoelH.G. van der KwastT.H. RouvièreO. SchootsI.G. WiegelT. CornfordP. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent.Eur. Urol.201771461862910.1016/j.eururo.2016.08.00327568654
     [Google Scholar]
  8. CornfordP. van den BerghR.C.N. BriersE. Van den BroeckT. CumberbatchM.G. De SantisM. FantiS. FossatiN. GandagliaG. GillessenS. GrivasN. GrummetJ. HenryA.M. der KwastT.H. LamT.B. LardasM. LiewM. MasonM.D. MorisL. Oprea-LagerD.E. der PoelH.G. RouvièreO. SchootsI.G. TilkiD. WiegelT. WillemseP.P.M. MottetN. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: Treatment of relapsing and metastatic prostate cancer.Eur. Urol.202179226328210.1016/j.eururo.2020.09.04633039206
     [Google Scholar]
  9. Highlights of prescribing information ® (degarelix for injection) for subcutaneous administration.Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022201s009lbl.pdf
  10. Highlights of prescribing information.Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
  11. AgarwalaA. BansalS. GuptaN.P. Bilateral orchidectomy revisited in management of metastatic hormone-sensitive prostate cancer.Indian J. Surg. Oncol.202112356557010.1007/s13193‑021‑01390‑w34658587
     [Google Scholar]
  12. AguilarA. PlanasJ. TrillaE. MoroteJ. Methods for evaluating the efficacy of medical castration: A systematic review.Cancers20231513347910.3390/cancers1513347937444589
     [Google Scholar]
  13. NakataD. MasakiT. TanakaA. YoshimatsuM. AkinagaY. AsadaM. SasadaR. TakeyamaM. MiwaK. WatanabeT. KusakaM. Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice.Eur. J. Pharmacol.201472316717410.1016/j.ejphar.2013.12.00124333551
     [Google Scholar]
  14. European Medicines Agency Firmagon (degarelix): EPAR-product information.2022Available from: https://www.ema.europa.eu/en/documents/product-information/firmagon-epar-product-information_en.pdf
  15. Center for Drug Evaluation and Research Center for Drug Evaluation and Research. Firmagon (degarelix): CDER medical review.2008Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_SumR.pdf
  16. CordesL.M. KarzaiF. FiggW.D. MadanR.A. Relugolix in clinical practice: The best route for all?Oncologist202328864765010.1093/oncolo/oyad09937162497
     [Google Scholar]
  17. European Medicines Agency. Orgovyx 120 mg flm-coated tablets: Summary of product characteristics.2022Available from: https://www.ema.europa.eu/en/documents/product-information/orgovyx-epar-product-information_en.pdf
  18. SonessonA. RasmussenB.B. In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker.Drug Metab. Dispos.20134171339134610.1124/dmd.113.05170623589543
     [Google Scholar]
  19. MacLeanDB ShiH FaesselHM Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): Phase 1 study in healthy males.J Clin Endocrinol Metab20151001245794587
     [Google Scholar]
  20. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Clinical drug interaction studies - Cytochrome P450 enzyme - and transporter-mediated drug interactions guidance for industry.2020Available from: https://www.fda.gov/media/134581/download
  21. De La CerdaJ. DunsheeC. GervasiL. SieberP. BelkoffL. TutroneR. LuS. GatoulisS.C. BrownB. MigoyaE. ShoreN. A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced prostate cancer.Target. Oncol.202318338339010.1007/s11523‑023‑00967‑537060432
     [Google Scholar]
  22. ShoreN.D. Experience with degarelix in the treatment of prostate cancer.Ther. Adv. Urol.201351112410.1177/175628721246104823372607
     [Google Scholar]
  23. Boccon-GibodL. van der MeulenE. PerssonB.E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.Ther. Adv. Urol.20113312714010.1177/175628721141445721904569
     [Google Scholar]
  24. US FDA Relugolix: Multi-disciplinary review.2020Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf
    [Google Scholar]
  25. ShirleyM. Relugolix: A review in advanced prostate cancer.Target. Oncol.202318229530210.1007/s11523‑022‑00944‑436652173
     [Google Scholar]
  26. ShoreN.D. AbrahamssonP-A. AndersonJ. CrawfordE.D. LangeP. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Prostate Cancer Prostatic Dis.201316171510.1038/pcan.2012.2522751146
     [Google Scholar]
  27. Van PoppelH. TombalB. de la RosetteJ.J. PerssonB.E. JensenJ.K. Kold OlesenT. Degarelix: A novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.Eur. Urol.200854480581510.1016/j.eururo.2008.04.06518538469
     [Google Scholar]
  28. GittelmanM. PommervilleP.J. PerssonB.E. JensenJ.K. OlesenT.K. Degarelix Study Group A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.J. Urol.200818051986199210.1016/j.juro.2008.07.03318801505
     [Google Scholar]
  29. KlotzL. Boccon-GibodL. ShoreN.D. AndreouC. PerssonB.E. CantorP. JensenJ.K. OlesenT.K. SchröderF.H. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.BJU Int.2008102111531153810.1111/j.1464‑410X.2008.08183.x19035858
     [Google Scholar]
  30. TombalB. MillerK. Boccon-GibodL. SchröderF. ShoreN. CrawfordE.D. MoulJ. JensenJ.K. Kold OlesenT. PerssonB.E. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.Eur. Urol.201057583684210.1016/j.eururo.2009.11.02919962227
     [Google Scholar]
  31. ShoreN.D. SaadF. CooksonM.S. GeorgeD.J. SaltzsteinD.R. TutroneR. AkazaH. BossiA. van VeenhuyzenD.F. SelbyB. FanX. KangV. WallingJ. TombalB. HERO Study Investigators Oral relugolix for androgen-deprivation therapy in advanced prostate cancer.N. Engl. J. Med.2020382232187219610.1056/NEJMoa200432532469183
     [Google Scholar]
  32. O’FarrellS. GarmoH. HolmbergL. AdolfssonJ. StattinP. Van HemelrijckM. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.J. Clin. Oncol.201533111243125110.1200/JCO.2014.59.179225732167
     [Google Scholar]
  33. BoscoC. BosnyakZ. MalmbergA. AdolfssonJ. KeatingN.L. Van HemelrijckM. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis.Eur. Urol.201568338639610.1016/j.eururo.2014.11.03925484142
     [Google Scholar]
  34. Orgovyx (relugolix).Myovant SciencesBrisbane, CA2022
     [Google Scholar]
  35. AlbertsenP.C. KlotzL. TombalB. GradyJ. OlesenT.K. NilssonJ. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.Eur. Urol.201465356557310.1016/j.eururo.2013.10.03224210090
     [Google Scholar]
  36. MargelD. PeerA. BerY. Shavit-GrievinkL. TabachnikT. SelaS. WitbergG. BanielJ. KedarD. DuivenvoordenW.C.M. RosenbaumE. PinthusJ.H. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease.J. Urol.201920261199120810.1097/JU.000000000000038431188734
     [Google Scholar]
  37. GeorgeG. GarmoH. ScailteuxL.M. BalussonF. De CosterG. De SchutterH. KuiperJ.G. OgerE. VerbeeckJ. Van HemelrijckM. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.Int. J. Cancer202114892203221110.1002/ijc.3339733186481
     [Google Scholar]
  38. LopesR.D. HiganoC.S. SlovinS.F. NelsonA.J. BigelowR. SørensenP.S. MelloniC. GoodmanS.G. EvansC.P. NilssonJ. BhattD.L. ClarkeN.W. OlesenT.K. Doyle-OlsenB.T. KristensenH. ArneyL. RoeM.T. AlexanderJ.H. Mol-ArtsM. Mansor-LefebvreS. ZubovskiyK. BlemingsA. DugiK. BloomfieldG. KontosC. DeVoreA. JordanD. KollsB. MatthewsR. MehtaR. PovsicT.J. MorseM. MahaffeyK.W. HalabiS. LeongD. KlotzL. FleshnerN. JanszG. GiddensJ. EgerdieR. ChinJ. ZadraJ. CaseyR. SimardJ. NiaziT. MartinA-G. BabjukM. HajekJ. KleckaJ. KubesJ. SchramlJ. JakesovaJ. VanasekJ. MelicharB. SeikkulaH. AbdicheM.S. ColombelM. DebourdeauP. RobertG. VillersA. PloussardG. PradereB. BruyereF. DescotesJ-L. OuzaidI. WinterA. HanitzschH. SperlingH. EckertR. HammererP. StaggeE. SesekeF. SzymulaS. BamiasA. ThanosA. HatzimouratidisK. MamoulakisC. KalofonosH. OszukowskaE. MadziarskaK. FijuthJ. ObarzanowskiM. AlekseevB. AtduevV. PushkarD. VelievE. ZyryanovA. PetrovS. KopyltsovE. KozlovV. MackoL. DubravickyJ. PolakR. MirO. VargovcakM. MincikI. KlimentJ. GoncalvesF. MikulasJ. SokolR. KorcekM. MarkoJ. KovacikV. MilichovskyI. DubinskyP. LazarusJ. DixitS. GreenE. SrinivasanR. MazharD. NgY. SarwarN. HermanC. SnoyF. GivenR. SuhR. LipsitzD. BailenJ. GervasiL. AcostaI. BelkoffL. WuN. FrankelJ. KarshL. PooleB. LieberD. EngelJ. BidairM. RosenbergS. SieberP. PerzinA. KalotaS. SinghA. HendersonR. WayneJ. MirzaM. D’AnnaR. WolkF. PadronO. BylowK. RubensteinJ. GartrellB. SchwartzM. PatelK. ManiamA. KeaneT. GoodmanM. BaneC. ChungM. SavageS. UchioE. NguyenS. AronsonW. KhannaR. BarnswellC. PRONOUNCE Study Investigators Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: The primary results of the PRONOUNCE randomized trial.Circulation2021144161295130710.1161/CIRCULATIONAHA.121.05681034459214
     [Google Scholar]
  39. US National Library of Medicine Relugolix versus leuprolide cardiac trial (revelution).N.C.T. Patent 05320406,2024
  40. Randomized study to evaluate MACE in patients with prostate cancer treated with relugolix or leuprolide acetate.N.C.T. Patent 05605964,2024
  41. BlackwoodC. SangaP. NuamahI. KeenanA. SinghA. MathewsM. GopalS. Patients’ preference for long-acting injectable versus oral antipsychotics in schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.Patient Prefer. Adherence2020141093110210.2147/PPA.S25181232753849
     [Google Scholar]
  42. Lexi-drugs.Available from: https://online.lexi.com
/content/journals/cdth/10.2174/0115748855324045240902100500
Loading
A Pharmacological Overview of Degarelix and Relugolix in Advanced Prostate Cancer
Curr Drug Ther 20, 785 (2025); https://doi.org/10.2174/0115748855324045240902100500
/content/journals/cdth/10.2174/0115748855324045240902100500
/content/journals/cdth/10.2174/0115748855324045240902100500
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): castration; degarelix; GnRH antagonists; pharmacology; Prostate cancer; relugolix

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test